Pharma Technology Focus is free for the iPad. Download our app to read the latest issue and browse our back issues for free
Treatment for many serious diseases is still inadequate, an issue that is highlighted in the World Health Organization’s Priority Medicines for Europe and the World Report. Taking a closer look at some of the diseases at the top of the WHO’s agenda – from dementia to antibiotic resistance and osteoarthritis – we ask what progress has been made in improving therapeutic standards.
China’s healthcare system is undergoing reform, creating new opportunities for foreign players, but challenges remain in the form of regulatory hurdles, pricing reforms and growing local competition. We take a look inside one of the world’s most rapidly growing pharma markets.
We also find out how GSK is planning to revitalise its product pipeline with a new wave of innovative treatments in areas including HIV, oncology, respiratory medicine and rare diseases, and hear from GlobalData about new findings in the treatment of multiple myeloma. Plus, we take a look at new digital tools for setting up and managing clinical trials, and we speak to University of California researchers about the potential applications for a model they have developed to predict a drug’s side effects on different patients.
In this issue
A Giant Emerges China’s pharmaceutical market will be the world’s second largest by 2016, creating opportunities for international players, but challenges remain in the form of regulatory hurdles, pricing reforms and growing local competition, as Elly Earls reports.Read the article.
GSK: The Next Generation GlaxoSmithKline is pursuing an ambitious long-term strategy with some 40 new drugs in development. Elly Earls takes a look at the potential of the company’s new portfolio.Read the article.
Priority PathwaysTreatment for many serious diseases is still inadequate around the world. Looking at case studies from dementia to antibiotic resistance and osteoarthritis, Chris Lo asks what is being done to improve therapeutic standards.Read the article.
Hope for Multiple Myeloma PatientsDan Roberts, PhD, GlobalData’s senior analyst for oncology and hematology, reports on new findings in the treatment of multiple myeloma.Read the article.
Streamlining Trials: New Tools on the MarketNew solutions for the start-up and management of clinical trials promise to streamline the process and save money. Abi Millar takes a look at some of the latest products on the market.Read the article.
Tackling Big Pharma’s Inconvenient TruthResearchers have developed a model that could predict a drug’s side effects on different patients. Elly Earls find out how this could impact on how treatments are prescribed and developed.Read the article.
Next issue preview
Russia has been boosting its credentials as a prime location for early-stage clinical trials, with 70% of new drugs registered in Europe in 2015 tested in phase I-II studies in the country. We explore Russia’s popularity as a trial location, including factors such as short enrolment periods, high recruitment rates and an improving regulatory framework.
We also find out how new research into the human microbiome could support the development of drugs that mitigate the effects of radical treatments such as chemotherapy on the body by modulating the activity of the microbiome. Also in this issue, Amplexor Life Sciences tells us how the life sciences sector can make the most out of real-time data and analytics tools, and we speak to Medidata about its efforts to integrate wearable health trackers into the drug development process to improve the collection of patient data.
Digital magazine FAQ
You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a in the app and never miss a new issue.
You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)